$PRVB News
Last published 5mo ago
- 5mo agoPRVBApproval of Tzield, Bla #761183FDA Approved DrugsApproval Date: 06/12/2026; Drug Name: Tzield, Bla #761183; Active Ingredients: TEPLIZUMAB-MZWV; Company: Provention Bio Inc; Submission Status: Approval; Application Number: 761183
- 3y agoPRVBPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.GlobeNewswireHart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc. Paris, France – April 26, 2023 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust
- 3y agoCVTPRVBRADIUNVRMoore Kuehn Encourages RADI, PRVB, CVT, and UNVR Investors to Contact Law FirmGlobeNewswireNEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoOSHPRVBSGENXMMoore Kuehn Encourages XM, OSH, SGEN, and PRVB Investors to Contact Law FirmGlobeNewswireNEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoFRCBACJPMSCHW+13Stocks making the biggest moves midday: First Republic Bank, Moderna, Newmont, Illumina and moreCNBCThese are the stocks posting the largest moves midday.
- 3y agoPRVBProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallPR NewswireRED BANK, N.J., March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the
- 3y agoPRVBTeplizumab in Pediatric Stage 2 Type 1 Diabetes - NCT05757713ClinicalTrials.govFrequency of TEAEs, AESIs, TEAEs leading to withdrawal, SAEs, Serum concentrations of teplizumab, Serum concentration of anti-teplizumab antibodies (ADA/NAb), Serum concentration of CD3 receptor occupancy on T cells
- 3y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., March 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced
- 3y agoPRVBProvention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023PR NewswireRED BANK, N.J., Feb. 23, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today
- 3y agoPRVBProvention Bio Announces Completion of $35 Million Equity Investment from Sanofi USPR NewswireCompanies collaborating to expand access to TZIELD™ (teplizumab-mzwv), the first approved disease-modifying therapy for type 1 diabetes RED BANK, N.J., Feb. 13, 2023 /PRNewswire/ -- Provention Bio, Inc.
- 3y agoPRVBProvention Bio to Present at the SVB Securities Global Biopharma ConferencePR NewswireRED BANK, N.J., Feb. 8, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will
- 3y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., Feb. 3, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that
- 3y agoHTGCPRVBProvention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®PR NewswireRED BANK, N.J., Feb. 2, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the
- 3y agoPRVBAGC Biologics Supports Commercial Production of Provention Bio's New Type 1 Diabetes (T1D) Therapy, TZIELD™Business WireThe Global CDMO's Seattle site continues work on this new T1D treatment, the first and only treatment approved to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
- 3y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., January 6, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced
- 3y agoPRVBProvention Bio Announces Appointment of Rita Jain, M.D., to Board of DirectorsPR NewswireRED BANK, N.J., Jan. 5, 2023 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the
- 3y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., Dec. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that
- 3y agoPRVBTZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1DPR NewswireTZIELD is the first disease-modifying therapy in T1D, a life-threatening autoimmune diseaseIn a clinical trial, in Stage 2 T1D patients, TZIELD delayed the median onset of Stage 3 T1D by 25 months, or approximately 2
- 3y agoPRVBFDA Approves First Drug That Can Delay Onset of Type 1 DiabetesFDA Press ReleasesToday, the U.S. Food and Drug Administration approved Tzield (teplizumab-mzwv) injection to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes. “Today’s approval of a first-in-class therapy adds an important new treatment option for certain at-risk patients,” said John Sharretts, M.D., director of the Division of ...
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., Nov. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that
- 4y agoPRVBProvention Bio Reports Third Quarter 2022 Financial Results and Provides Business UpdatePR NewswireContinues to Advance Preparations for Potential U.S. Commercial Launch of Teplizumab Ahead of November 17th FDA User Fee Goal Date RED BANK, N.J., Nov. 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a
- 4y agoPRVBProvention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022PR NewswireRED BANK, N.J., Oct. 13, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., Oct. 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that
- 4y agoPRVBProvention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk IndividualsPR NewswireProvention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D U.S. copromotion agreement leverages Sanofi's in-market infrastructure and established expertise in en
- 4y agoPRVBProvention Bio Announces Senior Leadership AdditionPR NewswireRED BANK, N.J., Sept. 19, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has appointed Sarah O'Brien
- 4y agoPRVBProvention Bio to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireRED BANK, N.J., Sept. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate virtually in a corporate pres
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., Sept. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to tw
- 4y agoHTGCPRVBProvention Bio Announces $125 Million Term Loan Facility with Hercules CapitalPR NewswireRED BANK, N.J., Aug. 31, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has secured a term loan faci
- 4y agoPRVBProvention Bio Reports Second Quarter 2022 Financial Results and Provides Business UpdatePR Newswire-Teplizumab Biologics License Application (BLA) user fee goal date extended to November 17, 2022- -Company completes $60.0 million private placement- RED BANK, N.J., Aug. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., Aug. 2, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to nine
- 4y agoPRVBProvention Bio to Report Second Quarter 2022 Financial Results on August 4, 2022PR NewswireRED BANK, N.J., July 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2022 financial results
- 4y agoPRVBProvention Bio Announces $60 Million Private PlacementPR NewswireRED BANK, N.J., July 7, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has entered into a securities purchase agre
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., July 5, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to a n
- 4y agoPRVBProvention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022PR NewswireRED BANK, N.J., June 30, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the U.S. Food and Drug Administration (F
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to eigh
- 4y agoPRVBProvention Bio to Present at the Jefferies Global Healthcare ConferencePR NewswireRED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at
- 4y agoPRVBProvention Bio Announces Update to Board of DirectorsPR NewswireRED BANK, N.J., June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced Dr. Jeffrey Bluestone's decision to step down as a director on
- 4y agoPRVBProvention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This YearPR NewswireRED BANK, N.J., May 12, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will host an investor event on Thursda
- 4y agoPRVBProvention Bio Reports First Quarter 2022 Financial Results and Provides Business UpdatePR Newswire-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022- -Company to host teplizumab commercial launch investor event on Thursday, May 19, 2022- RED BANK, N.J., May 5, 202
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., May 3, 2022 /PRNewswire/ --Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to four
- 4y agoPRVBProvention Bio to Report First Quarter 2022 Financial Results on May 5, 2022PR NewswireRED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2022 financial results
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., April 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two
- 4y agoPRVBProvention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101PR NewswirePRV-101 continued to be well tolerated and elicited durable high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers RED BANK, N.J., March 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceu
- 4y agoPRVBProvention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk IndividualsPR Newswire- FDA Sets Goal Date of August 17, 2022- -If Approved Teplizumab will be the First Disease-Modifying Therapy for Type 1 Diabetes - RED BANK, N.J., March 21, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutic
- 4y agoPRVBProvention Bio Announces the Grant of Inducement AwardsPR NewswireRED BANK, N.J., March 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to two
- 4y agoPRVBProvention Bio to Present at Two Upcoming Virtual Investor ConferencesPR NewswireRED BANK, N.J., March 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in two upcoming virtual inves
- 4y agoPRVBProvention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatePR NewswireRED BANK, N.J., Feb. 24, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended D
- 4y agoPRVBProvention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)PR NewswireRED BANK, N.J., Feb. 22, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced it has resubmitted the Biologics License Appl
- 4y agoPRVBProvention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022PR NewswireRED BANK, N.J., Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 fin
- 4y agoPRVBProvention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare ConferencePR NewswireRED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat